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Abstract
Background and objective  With the most recent introduction of microarray technology to biology, it becomes possible to 
perform comprehensive analysis of gene expression in cancer cell. In this study the laser microdissection technique and cDNA 
microarray analysis were combined to obtain accurate molecular profiles of lymphatic metastasis in patients with lung squamous 
cell carcinoma. 
Methods  Primary lung squamous cancer tissues and regional lymph nodes were obtained from 10 patients who underwent 
complete resection of lung cancer. According to the source of lung cancer cells, the samples were classified into three groups: 
the primary tumor with lymphatic metastasis (TxN+, n=5), the primary tumor without lymphatic metastasis (TxN-, n=5) 
and matched tumor cells from metastatic lymph nodes (N+, n=5). Total RNA was extracted from laser microdissected tumor 
samples. Adequate RNA starting material of mRNA from primary tumor or metastatic nodes were labeled and then hybridized 
into the same microarray containing 6 000 known, named human genes/ESTs. After scanning, data analysis was performed using 
GeneSpring
TM6.2. Results  A total of 37 genes were found to be able to separate TxN+ from TxN-. TxN+ have higher levels of 
genes concerned with structural protein, signal transducer, chaperone and enzyme. TxN- have higher levels of genes coding for 
cell cycle regulator, transporter, signal transducer and apoptosis regulator. Interestingly, there were no differentially expressed 
genes between N+ and TxN+. 
Conclusion  The acquisition of the metastatic phenotype might occur early in the development of lung squamous cancer. We 
raise the hypothesis that the gene-expression signature described herein is valuable to elucidate the molecular mechanisms 
regarding lymphatic metastasis and to look for novel therapeutic targets.
Key words  Lung neoplasms; Gene-expression; Lymphatic metastasis
DOI:10.3779/j.issn.1009-3419.2009.09.001     
This study was supported by grant from the scientific fund of the Ministry of Personnel for returned overseas expert (2006) and 
Natural Science Foundation Project of CQ CSTC (to Mingjian GE)(CSTC, No.2008BB5210).                                
【摘要】 背景与目的  筛选肺鳞癌患者淋巴转移差异表达基因群。方法  原发癌组织及区域淋巴结取自10例接受
完全性肺癌切除手术的肺鳞癌患者。根据组织来源将标本分为三组：不伴淋巴转移的肺鳞癌组织（TxN-, n=5）、伴
有淋巴转移的肺鳞癌组织（TxN+, n=5）及相应转移淋巴结中的肺鳞癌细胞（N+, n=5）。对各组进行激光显微切割以
获得纯净癌细胞，T7RNA线性扩增获取足够量的RNA，实验通道和参照通道分别标记以后与含6 000个已知人类基因
或表达序列标签的cDNA基因芯片杂交，扫描荧光信号以后进行数据分析。结果  共有37个基因可将TxN+组与TxN-组
区分开，其中在TxN+组高表达的基因有8个，主要涉及蛋白合成、信号传导、伴侣蛋白和酶等。有29个基因在TxN-组
高表达，这些基因主要编码细胞周期调节子、转导子、信号传导蛋白以及细胞凋亡调节蛋白。比较N+组与TxN+组却
没有发现具有显著性的差异表达基因。结论  肺鳞癌的淋巴转移表型的获得可能是早期事件。这些差异基因的发现有
助于阐明肺鳞癌淋巴转移的分子机制和寻找新的治疗靶点。
【关键词】 肺肿瘤；淋巴转移；基因表达
【中图分类号】 R734.2     
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Introduction 
The primary tumor may result from mutations in the 
growth control genes; meanwhile metastasis probably results 
mainly from change in gene expression pattern in the cell. Thus 
it is important to use new technologies for the identification 
and characterization of such genes in order to understand me-
tastasis and design better strategies to combat it
[1]. Biological 
experiments are frequently conducted in a manner that probes 
a single or a limited number of molecular markers that usually 
fail to provide satisfactory results for the studied procedure. 
With the most recent introduction of microarray technology to 
biology, it becomes distinctly possible to perform comprehen-
sive analysis of gene expression in cancer cells, and can reveal 
detailed phenotypic and biological information about cancer 
cells
[2,3]. In this study we coupled the laser microdissection 
(LMD) technique with cDNA microarray analysis that enable 
us to obtain accurate molecular profile of lymphatic metastasis 
in patients with lung squamous cancer without contamination 
of tumors by stromal cell etc.
Materials and methods 
Patients and tissue sample  
Primary lung squamous cancer tissues and regional lymph 
nodes were obtained with informed consent from 10 patients 
who underwent radical resection in our hospital in 2004. 
Clinical and pathological feature of the patients investigated 
are presented in Tab 1. According to the source of cancer cells, 
the cases were classified into three groups: the primary tumor 
with lymphatic metastasis (TxN+, n=5), the primary tumor 
without lymphatic metastasis (TxN-, n=5) and matched tumor 
cells from metastatic lymph nodes (N+, n=5). No significant 
differences were seen among the two groups of patients as far 
as age, sex, smoking history and type of tumor is concerned. 
None of the patients had a previous history of lung cancer or 
a concurrent malignancy, nor had they been exposed to any 
chemoradiotherapy. Tissues were snap frozen in liquid nitro-
gen and then stored at –80 
oC. For all cases, the diagnosis was 
established on routine formalin-fixed paraffin-embedded mate-
rial.
Laser Microdissection  
Frozen section from primary and metastatic lesions were 
stained with haematoxylin and eosin to verify the presence of 
viable tumor. Serial 8-μm thick sections were prepared with 
cryostat (Leica CM1900, Germany), and mounted on slides 
for membrane-based laser microdissection (Leica, Germany). 
The sections were laser microdissected with an LMD system 
(Leica Microsystems, Wetzlar, Germany). The fragments dis-
sected were collected in cups and 20 μL lysis solution were 
added (from RNAqueous-Micro Kit). An electronic image of 
the H&E stained section was used as a template to guide dis-
section of adjacent section. Fig 1 shows a typical procedure of 
microdissection of lung cancer cells. After cutting, 80 μl of lysis 
solution was added into the tube to dissolve the connective tis-
sue in order to release the cells which is collected at the bottom 
of tube. 
T7-based RNA amplification
Total RNA was extracted from microdissected lung squa-
mous cancer samples using the RNAqueous-Micro Kit (Am-
bion, Austin, Texas), according to manufacturer instruction. 
Adequate RNA starting material was generated using a T7 
RNA polymerase-catalyzed linear amplification method. The 
Amino Allyl MessageAmp
TM aRNA kit (Ambion, Austin, Tex-
as) was used in 2 successive rounds on all LMD-isolated RNA 
samples, according to manufacturer instruction. The Universal 
Human Reference total RNA (StrtageneR, Amsterdam, The 
Netherland) was used.
Labeling, hybridization and scanning
Ten-microgram aliquate of mRNA from primary tumor or 
metastatic nodes were labeled with Cy3 monofunctional dye 
(Amersham Biosciences UK Ltd., Bukes, United Kingdom) for 
the sample RNA and Cy5 monofunctional dye for the refer-
ence RNA and then hybridized onto the same microarray. The 
microarray used in this study were human cDNA microarrays, 
from the Sanger Center (Hixton, Cambridge, UK) as part of 
the LICR (the Ludwig Institute of Cancer Research)/CRUK 
Consortium. Each array contains 10 750 spots representing 
9 932 sequence-validated cDNA elements for 6 000known, 
named human genes/ESTs. cDNA microarray chips were hy-
bridized for 18 h in a 42 
oC incubator. After hybridization, the 
slides were washed once with 2×standard saline citrate (SSC) 
for 10 min at room temperature, 0.1×SCC/0.1% sodium 
dedecylsulfate three times for 20 min at 55 
oC, and then 0.1×
SCC twice for 5 min at room temperature. Both Cy3 and Cy5 
fluorescent images of hybridized microarray were captured 
using GSI Lumonics 4 000 scanner and ScanArray software 
(Perkin-Elmer Life Sciences Inc., Boston, Massachusetts)
Data Analysis  
After scanning, data were recorded as paired 16-bit TIFF 
images. Raw images were quantified using QuantArray 3.0 soft-
ware (Perkin-Elmer Life Science Inc., Boston, Massachusetts). 
Data analysis was performed using GeneSpring
TM6.2 (Silicon 
Genetics, Redwood City, California). For each microarray, the 
median intensity of all spots in each channel was normalized 
to the median intensity of the spots in the control channel. The 
spots intensities used to calculate the median value for nor-
malization were always background subtracted. The intensity 
dependent LOWESS normalization was then applied followed 
by per-chip normalization. The normalized intensity measure-
ments from each experiment were log transformed (base 2) 
and the log ratio of experimental vs. reference channel was 
used as the measure of gene expression. Then the normalized 
log ratio of the data was ready for further analysis. The signifi-
cance of altered expression of each gene was evaluated by one-
way ANOVA Welch t-test. We used the Bonferroni procedure 
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(Multiple Testing Correction) to control the false discovery 
rate (FDR).
An agglomerative hierarchical clustering was applied for 
both genes of interesting and samples from comparison of 
TxN+ vs TxN-.
Results 
There were 8 genes that were significantly overexpressed in 
TxN+, which mainly concerned with structural protein, signal 
transducer, chaperone and enzyme. On the other hand, there 
were 29 genes that were significantly up-regulated in TxN-, 
which mainly code for cell cycle regulator, transporter, signal 
transducer and apoptosis regulator (Tab 2). A scatter plot of 
microarray analysis and a gene/condition tree were showed 
in Fig 2 and Fig 3, respectively. Interestingly, according to the 
current filters, there were no differentially expressed genes be-
tween N+ and TxN+. 
Discussion
    Microarray technologies, based on hybridization meth-
ods first employed nearly 30 years ago
[4], have facilitated the 
analysis of expression level of thousands of genes in a single 
experiment. This technology is a powerful tool for analyzing 
gene expression profiling and has exerted profound impact 
on cancer studying. This tool is uniquely suited for molecular 
characterization: large numbers of genes can be simultaneously 
investigated, and the resulting gene expression patterns can 
be correlated with certain clinical parameters
[5]. Since then, 
researchers have used gene expression pattern to reveal previ-
ously unknown cancer categories
[6]. The clinical outcome of in-
dividuals with cancer can be predicted using the gene-expres-
sion profiles of primary tumors at diagnosis
[7-11]. In addition, 
analyses of gene expression profiles could reveal the identify of 
genes involved in malignant transformation, progression, and/
or metastases of tumors.
Tumor consists of mixed populations of carcinoma cells and 
host cells. It is imperative to study the gene-expression profile 
of each population consisting of tumor tissue to clearly under-
stand the molecular changes in the procedure of metastasis. 
The cDNA microarray method is now widely used to analyze 
expression of thousands of gene simultaneously in cancer tis-
sue and so on. But some of the gene expression differences that 
distinguished primary and metastatic tumor were contributed 
by the small amount of contaminating nonneoplastic lung tis-
sue present in the primary tumor samples
[12]. As expected, mi-
crodissection of tumor tissues can provide stroma-free tumor 
material in small amounts that are adequate for the molecular 
genetic analysis of particular mechanisms responsible for HLA 
class I alterations
[13].
One of the challenges of LMD is to obtain sufficient amount 
of RNA from captured cell populations. Total RNA (10 μg) 
from 50 000 cells was reported to be the detection limit for 
direct-labeling approaches
[14]. The most critical hurdle is to 
Sample No.  Source  T-stage  Smoking  Age/Sex
      1
#                        TxN+, N+        T1          Y  72/M
      2
#                        TxN+, N+        T3          Y   69/M
      3
#                        TxN+, N+        T2          N  62/M
      4
#                        TxN+, N+        T2          Y  76/F
      5
#                       TxN+, N+        T1          Y  61/M
     6
#                            TxN-        T2          Y  75/M
     7
#                            TxN-        T3          Y  66/M
     8
#                            TxN-        T2          Y  62/M
     9
#                            TxN-        T1         N  72/M
    10
#                            TxN-        T2         N  51/M
Tab 1  The clinical and pathological feature of the studied cases
TxN+, primary tumor with lymphatic metastasis; TxN-, primary tumor 
without lymphatic metastasis; N+, tumor from metastatic lymph nodes; Y, 
Yes; N, No; M, Male; F, Female.
Fig 1  A typical procedure of microdissection for lung cancer cells
A: Before cutting the cancer cells; B: After cutting the cancer cells; C: the 
dissected cancer cells.
C
B
A
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Tab 2  List of genes with altered expression between primary lung squamous cancer with lymphatic metastasis (TxN+) and without lymphatic       
               metastasis (TxN-)
Systematic name         Symbol                                    Description                                                       Classification of  molecular function                                Ratio
52277_A                     HKR3      GLI-kruppel family member HKR3                                            Nucleic acid binding                                                        0.433
41853_A                    TK2      Thymidine kinase 2, mitochondrial                                            Enzyme                                                                               0.357
323346_C                    RGS3      Regulator of G-protein signaling 3                                            Enzyme; Signal transducer                                                   0.283
40266_A                     FRAP1     Fk506 binding protein 12-rapamycin associated protein 1               Cell cycle regulator; enzyme; nucleic acid binding    0.472
299994_A                    TNNI3      Troponin I, cardiac                                                                                           Unclassified                                                                               0.401
33803_A                     MLH3      Mut L homolog 3 (E.coli)                                                                    Nucleic acid binding                                                        0.239
365687_B                      IL18BP      Interleukin 18 binding protein                                                                    Unclassified                                                                               0.390
282055_A                    PHKA2      Phosphorylase kinase, alpha 2 (liver)                                            Enzyme                                                                               2.018
28488_A                    HIP2      Huntingtin-interacting protein 2                                            Unknown                                                                               0.371
669500_A                    HIPK1        Homeodomain interacting protein kinase 1                                           Enzyme; nuleic acid binding                                0.156
262407_A                    NPC2      Niemann-Pick disease, type C2                                                                    Unclassified                                                                               0.355
38829_A                    PTPRR      Protein tyrosine phosphatase, receptor type, R                    Enzyme; structural protein                                2.774
813179_A                     IGF1      Insulin-like growth factor 1 (Somatomedin C)                                     Nucleic acid binding; signal transducer                          2.518
267950_A                                                                                                                                              Unknown                                                                               0.462
33182_C                                                                                                                                               Unknown                                                                                     0.197
41984_A                     G3BP2      Ras-GTPase activating protein SH3 domain-binding protein 2     EST                                                                               3.377
1839895_A                 PSMB2      Proteasome (prosome, macropain) subunit, beta type, 2                   Ubiquitin                                                                               2.970
280890_A                   EXT2      Exostosin 2                                                                                            EST                                                                               0.173
457710_A                   SV2A      Synaptic vesicle glycoprotein 2A                                                                   Transporter                                                                               0.196
297676_A                   FBLN2      Fibulin 2                                                                                                                  Structural protein                                                       0.309
428420_B                                                                                                                                              Unknown                                                                               0.261
34313_A                    OGT      O-linked N-acetylblucosamine (GlcNAc)                                               Enzyme                                                                               0.211
                                                                           transferase (UDP-N-acetylglucosamine: 
                                                                           polypeptide-N-acetylglucosaminyl transferase) 
40608_A                    HCRTR1      Hypocretin (orexin) receptor 1                                                                    Signal transducer; structural protein                               0.262
324225_B                   RARRES3      Retinoic acid receptor responder (tazarotene induced) 3                  Unclassified                                                                               0.258
295568_A                    HIP2      Huntingtin interacting protein 2                                            Enzyme; nucleic acid binding;  ubiquitin        0.300
40699_A                     PPP2R2B      Protein phosphatase 2, regulatory subunit B, beta                    EST                                                                               0.203
343142_A                   MGC40157      Hypothetical protein MGC40157                                            Tumor suppressor                                                       2.725
741459_A                    ATP5G3      ATP synthase, H+ transporting, mitochondrial F0 complex,          Enzyme; transporter                                                       0.215
                                                                           subunit C (subunit 9) isoform 3 
1874367_A                CCL20      Chemokine (C-C motif) ligand 20                                            Immunity protein; signal transducer                               0.336
470031_A                  PLA2G2A      Phospholipase A2, group ILA (platetets, synovial fliud)                   Enzyme; signal transducer                                0.140
346956_A                 APOC1      Apolipoprotein C-I                                                                                           Transporter                                                                               0.210
788591_A                LTBP1      Latent transforming growth factor beta binding protein 1               Signal transducer; structural protein                               0.177
51532_A                 ARL6IP      ADP-ribosylation factor-like 6 interacting protein                    EST                                                                               2.042
46100_B                 KIAA0753      KIAA0753 gene product                                                                   Unknown                                                                               0.351
26888_A                CDC42EP2      CDC42 effector protein (Rho GTPase binding) 2                    Chaperone; enzyme; structural protein                          2.506
29786_A                SON      SON DNA binding protein                                                                   Apoptosis regulator; nucleic acid binding                       0.278
111974_B                HMGCS1      3-hydroxy-3-methylglutaryl-coenzyme                                                                                                                                                               0.218
                                 A synthase 1(soluble)
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establish an unbiased global amplification procedure. However 
PCR is unsuitable to globally amplify the entire transcriptome 
of cells
[15]. Currently, most microarray amplification methods 
make use of a linear-based amplification method using T7RNA 
polymerase, resulting in an amplified RNA (aRNA) that can 
be used for hybridization analysis
[16]. Most microarray studies 
that utilize the aRNA synthesis protocol require one amplifi-
cation round. Due to the small amount of cellular material in 
this study, we performed a second round of amplification for 
all the microdissected cells and used the antisense RNA for 
hybridization analysis successfully. It was reported, at this level 
of amplification, the transcriptome of a single cell can be ana-
lyzed
[17].
Expression analysis with cDNA arrays showed distinct pro-
file between TxN+ and TxN- in patients with lung squamous 
cancer; however there was no differentially regulated genes 
between N+ and TxN+. This interesting finding supports the 
notion that some primary lung squamous cancer are pre-con-
figured to metastasize, and that this propensity is detectable at 
the time of initial diagnosis. We insisted on that acquisition of 
the metastatic phenotype might not necessarily occur late in 
the development of lung squamous cancer. Some primary lung 
squamous cancer may actually start out deadly to begin with. 
Bernards and Weinberg
[18]recently posited that combination 
of early oncogenic alterations, not specific events that promote 
metastasis, determine metastatic potential. This might explain 
why metastasis occurs in some individuals with small, low-
stage tumor or metastases could be found in the absence of 
clinically detectable primary tumor. 
Metastasis, the major cause of cancer morbidity and mor-
tality, is a multiple process requiring a variety of genetic al-
terations in the tumor cells. Comprehensive analysis of gene 
expression profiles between primary tumors with or without 
metastasis or a primary tumor and its derived tumors can 
identify differential genes associated with the metastatic phe-
notype, which help to elucidate the molecular mechanism of 
cancer metastasis
[19]. In the study, comparison of primary lung 
squamous cancer with/without lymphatic metastasis revealed 
37 significant alterations in the expression of metastatic-related 
genes, including up-regulation of IGF1, PTPRR and down-
regulation of PLA2G2A, FBLN2 as well as CCL20. IGF1 
may promote invasiveness in lung cancer cell through their 
ability to induce not only cell migration, but also by enhanc-
ing the expression and activity of matrix degrading MMP-2 
and MMP-9
[20]. For the patients with lung cancer, the serum 
IGF1 level was higher in cases with lymphatic metastasis
[21].
The circulating IGF-1 levels play an important role in colon 
cancer development and metastasis
[22]. PTPRR (protein tyro-
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Fig 2  A scatter plot of microarray data analysis between TxN+           
and TxN- in patients with primary lung squamous cancer. The                   
differentially expressed genes remained as white, containing genes 
whose difference in expression between TxN+ and TxN- condition is 
statistically significantly. The remaining genes do not meet one-way 
ANOVA test.
TxN+ vs TxN-
Source
741459_A (P3)
470031_A (PLA2G2A; MOM1; PLA2B; PLA2L; PLA2S; PLAS1)
297676_A (DKFZp586A1519)
346956_A (APOC1)
323346_C (RGS3; C2PA; RGP3; FLJ20370; PDZ-RGS3)
33182_C
45710_A (SV2A)
29786_A (DBP-5)
295568_A (HIP2)
262407_A (NPC2; HE1; NP-C2; MGC1333)
299994_A (TNNI3)
40699_A (PPP2R2B)
41853_A (TK2)
280890_A (EXT2)
1874367_A (CCL20; CKb4; LARC; ST38; MIP3A; MIP-3a; SCYA20)
428420_B
669500_A (KIAA0630)
34313_A (OGT; HRNT1; FLJ23071; MGC22921; O-GLCNAC)
40608_A (HCRTR1; OX1R)
788591_A (TGFB1)
111974_B (HMGCS1)
28488_A (HIP2)
46100_B (KIAA0753)
40266_A (FRAP2)
33803_A (MLH3)
324225_B (RIG1)
267950_A
365687_B (IL18BP)
282055_A (PHKA2; PYK; XLG; PYKL; XLG2)
38829_A (Ch-1PTPase alpha)
813179_A (IGF-1)
1839895_A (PSMB2; HC7-I)
41984_A (G3BP2)
343142_A (MGC40157)
51532_A (ARL6IP)
Fig 3  A gene/condition tree of samples from TxN+ or TxN- 
condition in patients with primary lung squamous cancer. Data 
are presented in a matrix format: each row represent a gene on the 
microarray and each column an individual mRNA sample. The 
results presented represent the ratio of hybridization of fluorescent 
cDNA probes prepared from each experimental mRNA sample to 
a reference mRNA sample. These ratios are a measure of relative 
gene expression in each experiment samples. All TxN+ samples are 
represented by a red branch and red block, all TxN- samples by yellow 
branch and block.
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sine phosphatase, receptor type, R) was strikely up-regulated 
in highly metastatic mouse hepatocarcinoma cell lines, sug-
gesting it is key gene responsible for lymphatic metastasis
[23].
PLA2G2A, a gene previously implicated as a modifier of the 
Apc (Min/+) (multiple intestinal neoplasia 1) mutant pheno-
type in the mouse, may suppress progression or metastasis of 
human gastric cancer
[24]. As an important regulator of invasion 
and metastasis, the invasive ability of PLA2G2A-expressing 
AGS cells was enhanced by PLA2G2A silencing, whereas 
cellular migrate in non-PLA2G2A-expressing N87 cells was 
inhibited by enforced PLA2G2A expression, indicating that 
PLA2G2A is both necessary and sufficient to function as an 
inhibitor of gastric cancer invasion in vitro. The antiinvasive ef-
fect of PLA2G2A occurs, at least in part, through its ability to 
inhibit the S100A4 metastasis mediator gene. Consistent with 
its invasion inhibitor role, PLA2G2A expression was elevated 
in metastatic and late-stage tumors
[25]. According to Wiese et 
al
[26], FBLN2 was associated with stromal cells. In our study, 
the gene was down-regulated in TxN+ group. We speculated 
that this gene is related to stroma-tumor interactions in lung 
cancer. Expression of the chemokine receptor CCR6, associat-
ed with the local production of CCR ligand, CCL20, decressed 
the metastatic potential of the Lewis lung carcinoma cell line, 
indicating CCL20 is an important regulator of metastasis
[27].
Interestingly there are no de-regulated genes in comparison of 
primary lung squamous cancer and its derived tumors in re-
gional lymph nodes.
Lymph-node metastasis is a key step in tumor progression 
and a risk factor for recurrence after surgery. These metastasis-
associated genes might serve as molecular marker for lymphat-
ic metastasis, which may provide clues to reveal patients with 
increase risk of developing metastasis, and to identify novel 
therapeutic targets for the treatment of metastasis. 
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